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INTRODUCTION
In the UK, lung cancer is the leading cause 
of cancer deaths and has a 5-year age-
standardised net survival rate of 13.3%.1,2 
The prognosis of patients diagnosed with 
lung cancer is strongly related to stage, 
and survival is better for patients diagnosed 
through primary care than for those 
diagnosed through emergency routes.3,4 
Therefore, much effort has been invested 
in improving the recognition of patients 
with suspected lung cancer presenting to 
primary care.
The symptoms of potential lung cancer 
reported by patients to their GPs and the 
positive predictive values of these symptoms 
have been identified.5 The National Institute 
for Health and Care Excellence (NICE) 
guidelines on the recognition and referral 
of suspected cancer were updated in 2015.6 
NICE recommends an urgent referral for 
patients with haemoptysis or an urgent 
chest X-ray for patients with lower-risk 
symptoms.6 
Current medical education still highlights 
haemoptysis as the cardinal symptom of 
lung cancer, and other symptoms such 
as dyspnoea and cough are downplayed.7 
While patients are likely to recognise the 
significance of haemoptysis, awareness of 
other symptoms and of the significance 
of cough is relatively low.8 However, this 
may be changing, particularly among 
patients, not least because recent symptom 
awareness campaigns have encouraged 
the public to see their GP if they have a 
cough, and because of increased attribution 
of this symptom to lung cancer.9–11
The aims of this study of patients with 
lung cancer were to:
• identify patients with lung cancer 
symptoms recorded before their lung 
cancer diagnosis (any-time symptom);
• identify patients’ first recorded symptom 
(index symptom); and
• to test whether the percentages of 
patients with each index symptom 
changed from 2000–2017.
METHOD
Study design and population
This serial, cross-sectional, observational 
study used data from the Clinical Practice 
Research Datalink (CPRD) with linked data 
from the National Cancer Registration and 
Analysis Service (NCRAS). The CPRD is 
a large database of coded, anonymised, 
electronic medical records created during 
everyday consultations from >600 UK 
general practices.12 Patients were included 
if they:
• were aged ≥18 years;
• had an incident diagnosis of lung cancer 
made between 1 January 2000 and 
31 December 2017; and
• were registered at a CPRD practice 
≥1 year before diagnosis.
The CPRD excluded patients with a 
previous diagnosis of cancer recorded in 
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Abstract
Background
Most patients diagnosed with lung cancer 
present with symptoms. It is not known if the 
proportions of patients presenting with each 
symptom has changed over time. Identifying 
trends in lung cancer’s presenting symptoms 
is important for medical education and early-
diagnosis initiatives.
Aim
To identify the first reported symptom of possible 
lung cancer (index symptom), and to test 
whether the percentages of patients with each 
index symptom changed during 2000–2017.
Design and setting
This was a serial, cross-sectional, observational 
study using UK Clinical Practice Research 
Datalink (CPRD) data with cancer registry 
linkage.
Method
The index symptom was identified for patients 
with an incident diagnosis of lung cancer in 
annual cohorts between 1 January 2000 and 
31 December 2017. Searches were constrained 
to symptoms in National Institute for Health 
and Care Excellence (NICE) suspected-cancer 
referral guidelines, and to the year before 
diagnosis. Generalised linear models (with 
a binomial function) were used to test if the 
percentages of patients with each index 
symptom varied during 2000–2017.
Results
The percentage of patients with an index 
symptom of cough (odds ratio [OR] 1.01; 
95% confidence interval [CI] = 1.00 to 1.02 
per year; P<0.0001) or dyspnoea (OR 1.05; 
CI = 1.05 to 1.06 per year; P<0.0001) increased. 
The percentages of patients with other index 
symptoms decreased, notably haemoptysis 
(OR 0.93; CI = 0.92 to 0.95; P<0.0001) and 
appetite loss (OR 0.94; CI = 0.90 to 0.97; 
P<0.0001).
Conclusion
During 2000–2017, the proportions of lung 
cancer patients with an index symptom of 
cough or dyspnoea increased, while the 
proportion of those with the index symptom 
haemoptysis decreased. This trend has 
implications for medical education and 
symptom awareness campaigns. 
Keywords
cancer; cough; diagnosis; dyspnoea; lung 
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their medical records using a comprehensive 
list of cancer codes. The research team 
excluded patients if they had multiple 
primary cancers diagnosed on the same 
day. The CPRD provided 27 889 potentially 
eligible participants; 94 patients with 
multiple primary cancers were excluded, 
leaving 27 795 eligible participants. 
Cancer diagnosis 
The cancer diagnosis date was derived from 
the earliest recorded cancer diagnostic 
code in the CPRD. Diagnosis type and 
date were validated by the linked NCRAS 
data where available, with the NCRAS 
date taking precedence where there 
were discrepancies. Only patients with an 
incident diagnosis of cancer were included. 
Symptoms
Lung cancer symptoms were those included 
in the NICE suspected-cancer referral 
guidelines, namely haemoptysis, cough, 
fatigue, dyspnoea, chest pain, weight loss, 
and appetite loss.6 Lists of Read Codes 
for these symptoms were collated using 
robust methods.13 Patients were classified 
as having experienced the symptom if 
they had a consultation with a Read Code 
corresponding to the symptom. ‘Any-time 
symptoms’ were defined as those that 
occurred in the year before diagnosis. 
The ‘index symptom’ was defined as the 
earliest recorded symptom. Multiple index 
symptoms on the same day were labelled 
as a ‘combination’ symptom, categorised by 
whether or not they included cough (the most 
prevalent symptom). In order to capture non-
specified presentations, consultations coded 
as ‘suspected cancer’ or ‘abnormal chest 
X-ray’ were identified where they preceded 
any recorded named symptoms. For annual 
cohorts of patients from 2000–2017, the 
numbers (and percentages) of patients with 
each symptom (both index and any-time) 
were reported.
Statistical analysis
The authors used a generalised linear model 
with a link function and a binomial probability 
distribution for the outcome variable, which 
was the number of patients with each index 
symptom. The explanatory variables were 
year of diagnosis (2000–2017), age, and sex. 
The model reported odds ratios (OR) for the 
outcome variable per year, with an OR>1.0 
representing an increase over time, and an 
OR<1.0 representing a decrease over time. 
RESULTS
After exclusions, 27 795 patients (44.4% 
female) with lung cancer, with a mean 
age of 72 years (standard error of the 
mean = 0.06 years), were studied. 
For each annual cohort, the numbers 
of patients with each index symptom and 
with each any-time symptom are shown 
in Tables 1 and 2, respectively. Of the 
27 795 patients, 1233 (4.4%) had a non-
specified primary care presentation of 
possible lung cancer occurring before a 
named symptom, of which 209 (0.8%) were 
an abnormal chest X-ray and 1024 (3.7%) 
were a suspected cancer code (Table 1). The 
percentage of patients with an abnormal 
chest X-ray preceding any symptoms 
decreased year on year (OR 0.89 per year; 
95% confidence interval [CI] = 0.86 to 0.91; 
P<0.0001). In contrast, the percentage of 
patients with a suspected-cancer code 
preceding any symptoms increased year on 
year (OR 1.08; CI = 1.07 to 1.96; P<0.0001). 
Of the 27 795 patients, 17 661 (63.5%) had a 
recorded lung cancer symptom. Cough was 
the most common index (n = 6781, 24.4%) or 
any-time (n = 9320, 33.5%) symptom. 
The percentages of patients with index 
symptoms of dyspnoea or cough (alone 
or in combination with another symptom) 
increased over time (Figure 1). Conversely, 
the other index symptoms, most notably 
appetite loss and haemoptysis, became 
less common over time (Figure 1). The 
percentages of patients with dyspnoea and 
cough as any-time symptoms increased 
over time and the percentages of patients 
with haemoptysis and appetite loss as 
any-time symptoms decreased over time 
(Figure 2).
How this fits in
The majority of patients with lung cancer 
present with symptoms; these symptoms 
and their positive predictive values for 
cancer have been identified. Using primary 
care records, this study looked for the 
first possible symptom of lung cancer 
(index symptom), and any trends over 
time in the proportions of patients with 
each index symptom. From 2000–2017, 
the percentages of patients with cough 
and dyspnoea as an index symptom 
increased. The percentages of patients 
with other index symptoms decreased, 
most notably for haemoptysis and 
appetite loss. Clinicians should be aware 
that, although haemoptysis remains an 
important symptom, its presentation is 
increasingly rare. Medical education needs 
to place at least as much emphasis on the 
more common symptoms of cough and 
dyspnoea as it does on haemoptysis. 
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Table 1. Number of patients with each index symptom occurring in the year before their lung cancer 
diagnosis for each annual cohort
Year of      Chest      Suspected  Weight Combination  Abnormal  Combination  Appetite  
cancer   Cough, Dyspnoea, pain, Fatigue, Haemoptysis, cancer, loss, cough +  chest X-ray, not including  loss, 
diagnosis Cohort N (%) N (%) N (%) N (%) N (%) N (%) N (%) other, N (%) N (%) cough, N (%) N (%)
2000 971 211 (22) 128 (13) 108 (11) 38 (4) 57 (6) 15 (2) 31 (3) 5 (1) 25 (3) 6 (1) 9 (1)
2001 1053 216 (21) 123 (12) 112 (11) 32 (3) 52 (5) 29 (3) 39 (4) 12 (1) 16 (2) 9 (1) 10 (1)
2002 1174 251 (21) 163 (14) 132 (11) 42 (4) 73 (6) 23 (2) 36 (3) 5 (0) 22 (2) 7 (1) 11 (1)
2003 1297 288 (22) 152 (12) 121 (9) 73 (6) 81 (6) 25 (2) 38 (3) 14 (1) 16 (1) 7 (1) 9 (1)
2004 1624 367 (23) 200 (12) 154 (9) 74 (5) 84 (5) 43 (3) 47 (3) 28 (2) 12 (1) 17 (1) 11 (1)
2005 1712 420 (25) 211 (12) 153 (9) 72 (4) 80 (5) 32 (2) 49 (3) 30 (2) 10 (1) 15 (1) 11 (1)
2006 1809 443 (24) 218 (12) 186 (10) 58 (3) 76 (4) 55 (3) 60 (3) 42 (2) 18 (1) 23 (1) 17 (1)
2007 1900 489 (26) 258 (14) 158 (8) 87 (5) 68 (4) 65 (3) 72 (4) 32 (2) 11 (1) 19 (1) 13 (1)
2008 1951 523 (27) 257 (13) 173 (9) 74 (4) 72 (4) 54 (3) 69 (4) 46 (2) 13 (1) 10 (1) 16 (1)
2009 1874 490 (26) 290 (15) 146 (8) 84 (4) 61 (3) 74 (4) 77 (4) 43 (2) 19 (1) 7 (0) 9 (0)
2010 1837 447 (24) 388 (21) 135 (7) 67 (4) 52 (3) 66 (4) 41 (2) 50 (3) 7 (0) 13 (1) 14 (1)
2011 1925 485 (25) 426 (22) 149 (8) 55 (3) 76 (4) 88 (5) 48 (2) 41 (2) 4 (0) 11 (1) 11 (1)
2012 1840 483 (26) 331 (18) 143 (8) 67 (4) 54 (3) 85 (5) 47 (3) 48 (3) 9 (0) 14 (1) 9 (0)
2013 1830 446 (24) 355 (19) 111 (6) 74 (4) 39 (2) 93 (5) 57 (3) 72 (4) 3 (0) 12 (1) 12 (1)
2014 1586 404 (25) 305 (19) 97 (6) 49 (3) 42 (3) 79 (5) 40 (3) 48 (3) 11 (1) 14 (1) 3 (0)
2015 1417 338 (24) 287 (20) 90 (6) 49 (3) 35 (2) 82 (6) 31 (2) 66 (5) 5 (0) 8 (1) 2 (0)
2016 1095 273 (25) 228 (21) 58 (5) 47 (4) 25 (2) 53 (5) 30 (3) 27 (2) 5 (0) 6 (1) 5 (0)
2017 900 207 (23) 197 (22) 57 (6) 22 (2) 16 (2) 63 (7) 17 (2) 22 (2) 3 (0) 7 (1) 2 (0)
Total 27 795  6781 4517 2283 1064 1043 1024 829 631 209 205 174
Table 2. Number of patients who reported each symptom or any symptom in the year before their lung 
cancer diagnosis for each annual cohort
Year of  Cohort,  Any symptom,  Cough,  Dyspnoea,  Chest pain,  Haemoptysis,  Weight loss,  Fatigue,  Appetite  
diagnosis N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) loss, N (%)
2000 971 601 (62) 263 (27) 195 (20) 161 (17) 109 (11) 57 (6) 69 (7) 21 (2)
2001 1053 614 (58) 288 (27) 201 (19) 174 (17) 104 (10) 67 (6) 56 (5) 25 (2)
2002 1174 724 (62) 317 (27) 255 (22) 196 (17) 121 (10) 59 (5) 71 (6) 23 (2)
2003 1297 788 (61) 379 (29) 278 (21) 192 (15) 133 (10) 71 (5) 101 (8) 36 (3)
2004 1624 993 (61) 484 (30) 352 (22) 241 (15) 164 (10) 101 (6) 119 (7) 34 (2)
2005 1712 1045 (61) 555 (32) 382 (22) 247 (14) 166 (10) 98 (6) 134 (8) 30 (2)
2006 1809 1131 (63) 602 (33) 406 (22) 305 (17) 157 (9) 120 (7) 109 (6) 44 (2)
2007 1900 1204 (63) 646 (34) 442 (23) 274 (14) 160 (8) 122 (6) 144 (8) 36 (2)
2008 1951 1244 (64) 680 (35) 462 (24) 269 (14) 142 (7) 117 (6) 128 (7) 36 (2)
2009 1874 1215 (65) 653 (35) 515 (27) 247 (13) 119 (6) 138 (7) 149 (8) 34 (2)
2010 1837 1212 (66) 643 (35) 630 (34) 253 (14) 135 (7) 91 (5) 129 (7) 39 (2)
2011 1925 1310 (68) 697 (36)  671 (35) 249 (13) 157 (8) 101 (5) 107 (6) 37 (2)
2012 1840 1211 (66) 670 (36) 563 (31) 250 (14) 128 (7) 90 (5) 107 (6) 27 (1)
2013 1830 1188 (65) 660 (36) 599 (33) 221 (12) 107 (6) 113 (6) 119 (7) 34 (2)
2014 1586 1009 (64) 583 (37) 484 (31) 188 (12) 80 (5) 81 (5) 83 (5) 25 (2)
2015 1417 914 (65) 519 (37) 460 (32) 167 (12) 77 (5) 62 (4) 85 (6) 15 (1)
2016 1095 706 (64) 388 (35) 343 (31) 112 (10) 60 (5) 53 (5) 68 (6) 14 (1)
2017 900 552 (61) 293 (33) 301 (33) 100 (11) 39 (4) 38 (4) 41 (5) 4 (0)
Total 27 795  17 661 9320 7539 3846 2158 1579 1819 514
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The analysis showed a statistically 
significant year-on-year increase in 
the percentages of patients with index 
symptoms of dyspnoea (OR 1.05; CI = 1.05 
to 1.06; P<0.0001) or cough (OR [cough 
alone] 1.01; CI = 1.00 to 1.02, P<0.0001; OR 
[cough plus another index symptom] 1.08; 
CI = 1.06 to 1.10; P<0.0001) (Table 3). There 
was a statistically significant decrease year-
on-year in the percentages of patients with 
index symptoms of haemoptysis (OR 0.93; 
CI = 0.92 to 0.95, P<0.0001), appetite loss 
(OR 0.94; CI = 0.90 to 0.97, P<0.0001), chest 
pain (0.96; CI = 0.95 to 0.97; P<0.0001), or 
weight loss (OR 0.98; CI = 0.96 to 0.99; 
P = 0.004) (Table 3). 
Table 3. Number of patients with each index symptom in the year before diagnosis with lung cancera
  Number of patients  Number of patients    
Index  diagnosed in 2000,  diagnosed in 2017,   
symptom  N = 971 (%) N = 900 (%) OR per year (95% CI) P-value
Increasing Combination (more than one 5 (1) 22 (2) 1.08 (1.06 to 1.10) <0.0001 
over time symptom including cough)
 Dyspnoea  128 (13) 197 (22) 1.05 (1.05 to 1.06) <0.0001
 Cough  211 (22) 207 (23) 1.01 (1.00 to 1.02) <0.0001
Decreasing Fatigue  38 (4) 22 (2) 0.99 (0.97 to 1.00) 0.0270 
over time Combination (more than one 6 (1) 7 (1) 0.98 (0.96 to 1.01) 0.3040 
 symptom excluding cough)
 Weight loss 31 (3) 17 (2) 0.98 (0.96 to 0.99) 0.004
 Chest pain  108 (11) 57 (6) 0.96 (0.95 to 0.97) <0.0001
 Appetite loss 9 (1) 2 (0) 0.94 (0.90 to 0.97) <0.0001
 Haemoptysis  57 (6) 16 (2) 0.93 (0.92 to 0.95) <0.0001
Total  593 (61) 547 (61)
aFor brevity, data for the intervening annual cohorts 2001–2016 are not shown. The odds ratio reports the change in proportion of patients with each index symptom per year, from 
2000–2017. OR = odds ratio.
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Figure 1. Index symptoms of lung cancer, 2000–2017.
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DISCUSSION
Summary
The percentages of patients presenting with 
symptoms of dyspnoea or cough before 
their lung cancer diagnosis increased from 
2000–2017. Conversely, the percentages 
of patients with lung cancer presenting 
with symptoms of haemoptysis or appetite 
loss declined, such that haemoptysis and 
appetite loss are now very rare presenting 
symptoms of lung cancer. 
Strengths and limitations 
The strengths of this study include the 
NCRAS linkage and the robust methods 
used for collating comprehensive code lists 
for symptoms.13 This study is limited by its 
use of Read Codes to establish if a patient 
has experienced a symptom. The Read 
Codes do not provide information about 
the duration and severity of symptoms 
or whether it was patient reported or 
doctor elicited. Some patients will have 
been misclassified if symptoms were not 
recorded or were noted in an irretrievable 
part of the medical records. Symptoms 
described in the free text were inaccessible. 
There is evidence that this may bias 
estimates in favour of established red-flag 
symptoms, such as haemoptysis, which are 
more likely than ‘low-risk but not no-risk’ 
symptoms to be recorded using codes.14 
Furthermore, a small number of patients 
had a non-specified presentation to primary 
care with ‘suspected cancer’ or abnormal 
chest X-ray codes, and these could not be 
classified further. 
Changes in coding practices and in the 
profile of general practices contributing 
data to the CPRD over time could have 
altered the estimates of the prevalence 
of recorded symptoms. Reassuringly, the 
proportion of patients with any recorded 
symptom was relatively constant over time, 
suggesting that any such changes were 
minor. The symptoms of lung cancer are 
shared with comorbidities, in particular 
chronic obstructive pulmonary disease 
(COPD). In theory, changes in the primary 
care management of COPD could have 
led to differences in symptom recording. 
The main driver of change in primary 
care COPD management was the Quality 
and Outcomes Framework introduced in 
2004, which encouraged documentation 
of chronic disease.15 However, there is no 
suggestion from Figure 1 that symptoms 
changed markedly around this date. 
Comparison with existing literature 
To the authors’ knowledge this is the first 
study to examine changes in the presenting 
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Figure 2. Trends in any occurrence of cough, shortness 
of breath, appetite loss, or haemoptysis in the year 
before diagnosis, by annual cohort.a
aTrends in the percentage of patients with any 
symptoms of possible lung cancer are also shown for 
reference. Values are percentages, and 95% confidence 
intervals are indicated by the dotted lines. 
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symptoms of lung cancer over time. 
Previous studies have also concluded that 
the commonest symptoms of lung cancer 
are cough and dyspnoea.16–19 In support 
of this study’s findings, Iyen-Omofoman 
et al17 found that only 248 of 12 074 (2.1%) 
patients with lung cancer diagnosed from 
2000–2009 experienced haemoptysis. Most 
other studies conclude that haemoptysis 
is more frequent, however, occurring in 
between 8.8% and 22.0% of patients before 
diagnosis.16,18,19 However, some of those 
studies were set in secondary care (where 
the symptom profiles differ markedly from 
those in primary care); were from a much 
earlier period (1998–2002); had smaller 
sample sizes; or examined longer pre-
diagnostic intervals.16,18,19
Implications for research and practice 
Future research is needed to investigate the 
association between symptoms and patient 
outcomes in order to explore if the observed 
trend in symptomatology represents earlier 
presentation of lung cancer. Continued 
research of patient factors influencing 
help-seeking behaviour for specific lung 
cancer symptoms would help improve 
understanding of the observed trends in 
symptomology. Specifically, it would be 
valuable to know if patients are becoming 
increasingly knowledgeable about lung 
cancer symptoms and whether this means 
that they are more willing to consult their 
GP about their symptoms. 
Haemoptysis remains an important 
presenting symptom of lung cancer as it 
has the highest positive predictive value.5 It 
is often thought of as the main presenting 
symptom of lung cancer, with a recent 
review stating that haemoptysis occurs in 
20% of patients with lung cancer.8 This study 
suggests that haemoptysis is actually a very 
rare symptom, and is becoming even more 
uncommon. Therefore, prominence should 
be given to other lung cancer symptoms in 
undergraduate and postgraduate education. 
Given that cough and dyspnoea are the 
most common presenting symptoms, 
continued targeting of these symptoms in 
public awareness campaigns may help to 
improve lung cancer diagnosis.
In summary, cough and dyspnoea are 
the most common presenting symptoms 
of lung cancer and from 2000–2017 the 
proportion of patients presenting with 
these symptoms has increased. In contrast, 
haemoptysis and appetite loss are now 
relatively rare presenting symptoms of lung 
cancer. Symptom awareness campaigns 
should target cough and dyspnoea. 
In addition, medical education needs to 
change, to avoid clinicians overlooking 
the importance of cough and dyspnoea as 
symptoms of undiagnosed lung cancer. 
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